Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis

Phase 3 Not yet recruiting 150 enrolled Vanda Pharmaceuticals

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ponesimod (VSP-128) in patients with moderately to severely active ulcerative colitis

Timeline

Start: 2026-09
Primary completion: 2029-04
Completion: 2029-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ponesimod	Small molecule	—	Oral

Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis

Summary

Timeline

Drugs

Indications